RUNX1 and acute myeloid leukemia: Nearly 33% of AML mutations in AYAs concern the NPM1 mutant phenotype, including DNMT3A, IDH1/2, and FLT3-ITD mutations, while “secondary-type” cytogenics, representing 13% of AML AYA patients, include RUNX1, MLL-PTD, and ASXL1 mutations [16].